cvc

Taurolidine 是一种广谱抗菌剂，用于预防中心静脉导管相关感染。它具有抗真菌和抗肿瘤作用。

DCVC inhibits pathogen-stimulated TNF-α in human extra placental membranes in vitro.Target: TNF-αin vitro: DCVC inhibits pathogen stimulated cytokine release from tissue punch cultures. DCVC (5-50 μM) significantly inhibits LTA-, LPS-, and GBS-stimulated cytokine release from tissue cultures as early as 4 h (P ≤ 0.05). In contrast, TCA (up to 500 μM) does not inhibit LTA-stimulated cytokine release from tissue punches. DCVC effects on LTA-stimulated and LPS-stimulated TNF-α release from tissue punch cultures of extraplacental membranes. DCVC effects on GBS-stimulated release of pro-inflammatory cytokines from extraplacental membranes in transwell cultures. [1]. Boldenow E, et al. The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine but not trichloroacetate inhibits pathogen-stimulated TNF-α in human extraplacental membranes in vitro. Reprod Toxicol. 2015 Apr;52:1-6. [2]. Lash LH, et al. Multigenerational study of chemically induced cytotoxicity and proliferation in cultures of human proximal tubular cells. Int J Mol Sci. 2014 Nov 18;15(11):21348-65. [3]. Yoo HS, et al. Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: kidney effects. J Toxicol Environ Health A. 2015;78(1):32-49.

HCVcc-IN-2 是一种具有低毒、抗病毒活性的苯并噻唑-2-噻吩 S-糖苷衍生物。

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC with potent antitumor activity, comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

MC-VC-PABC-DNA31 is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC) that demonstrates potent antitumor activity. It employs DNA31, an effective inhibitor of RNA polymerase, connected through the MC-VC-PABC ADC linker.

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate designed for Antibody-Drug Conjugates (ADCs), comprising Aur0101, an auristatin microtubule inhibitor, connected through the MC-VC-PABC linker to enhance antitumor efficacy.

SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the cleavable linker SC-VC-PAB[1].

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

MC-VC-PAB-NH2 is a cleavable linker vital in ADC synthesis. MC-VC-PAB-NH2 joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

MC-vc-PAB-Tubulysin M is a conjugate composed of a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, resulting in cell cycle arrest and apoptosis.

Mc-VC-PAB-SN38 由可降解 (cleavable) 的 ADC linker (Mc-VC-PAB) 和 SN38 组成，属于抗体偶联活性分子的一部分，常用来合成靶向作用位点的抗体偶联活性分子 (ADC)。

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) utilizing a protein-degrading agent (protac molecular glue, etc.).

VCMMAE (mc-vc-PAB-MMAE) 是一种用于 ADC 的药物-接头偶联物，具有抗癌活性，它由 MMAE 和 Vc 连接而成。

MC-VC-PAB-MMAD为一种抗体-活性分子偶联物，连接了微管抑制剂MMAD与可降解的ADC linker MC-VC-PAB。

MC-VC-PABC-SP 141 是抗体-活性分子偶联物的一部分，由有效的 MDM2抑制剂 SP 141 和可降解的 ADC linkerMC-VC-PABC 连接而成。

HCVCore Protein (59-68) 是一种含有 HCV 核心蛋白 59-68 残基的肽。

HCVCore Protein (107-114) 是主要线性 HCV 核心区域中免疫原性极低的残基。HCVCore Protein (107-114) 被鉴定为 101-118 区域内的结合位点，其包含基因型 Ⅰ Ⅱ 和基因型 Ⅲ Ⅵ 之间不同的两个残基。HCVCore Protein (107-114) 可能是传播 HCV 血清型的潜在位点。

MC-VC-PAB-NH2 TFA为一种可降解(cleavable)的ADC linker，适用于抗体偶联药物(ADC)的合成。

Bi-Mc-VC-PAB-MMAE是由ADC linker (Fmoc-Val-Cit-PAB) 与MMAE构成，后者为一种有效的(tubulin)抑制剂，用于偶联抗体。

GGGDTDTC-Mc-vc-PAB-MMAE为一种ADC药物-连接物偶联物，主要由微管蛋白抑制剂Monomethylauristatin E (MMAE)组成。

MC-VC-PAB-Cyclohexanediamine-Thailanstatin A 是一种药物-连接子偶联物，它结合了细胞毒素Thailanstatin A以及可切割的连接子(MC-vc-PAB)，用于抗体药物偶联物（ADC）的合成，属于剪接抑素类似物。

MC-VC-PABC-C6-alpha-Amanitin是一款针对HER2受体的ADC，包含致癌毒素alpha-Amanitin及单克隆抗体MC-VC-PABC-C6。alpha-Amanitin主要抑制RNA聚合酶IIα。该化合物专一性地靶向HER2阳性肿瘤细胞，主要应用于乳腺癌与胃癌的研究领域。